Clinical study on predicting the effectiveness of RDN in treating hypertension based on autonomic nervous function

Status

Recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2400083428

Enrollment

Unknown

Registered

2024-04-24

Start date

2023-06-15

Completion date

Unknown

Last updated

2024-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hypertension

Interventions

Divide patients into RDN responsive group and RDN unresponsive group based on their response to RDN treatment:None

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Diagnosed as primary hypertension 2. Age 18-75 years old 3. Those who voluntarily participate in this study and sign an informed consent form

Exclusion criteria

Exclusion criteria: 1. Taking ß Receptor blocker 2. The anatomical structure of the renal artery is not suitable for renal artery ablation 3. Glomerular filtration rate (eGFR) less than 45 ml/min/1.73m2 4. Secondary hypertension

Design outcomes

Primary

Measure	Time frame
Ambulatory blood pressure;clinic blood pressure and home blood pressure;	—

Secondary

Measure	Time frame
Heart rate variability;decelerration capacity of rate;heart rate deceleration runs;heart rate turbulence;blood pressure variability;Heart rate recovery;neurotensin;neuropeptide Y;	—

Countries

China

Contacts

Public ContactChen Chen

Putuo District Center Hospital, Shanghai

faithdefender@163.com+86 138 1813 2875

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026